CUPERTINO, Calif., Feb. 8 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today its financial results for the three months and
year ended December 31, 2005.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )
Our net loss for the three months ended December 31, 2005 was $6.0 million
or 10 cents per share, compared to a net loss of $7.0 million or 13 cents per
share for the same period in 2004. Our results for the three months ended
December 31, 2005 included non-cash charges of $438,000 for stock-based
compensation and the amortization of intangible assets, compared to $329,000
for the same period in 2004. Net cash used in operating activities was $5.6
million for the three months ended December 31, 2005, compared to $6.8 million
for the same period in 2004.
Our net loss for the year ended December 31, 2005 was $18.1 million or 34
cents per share, compared to a net loss of $27.6 million or 54 cents per share
for the same period in 2004. Our results for the year ended December 31, 2005
included non-cash charges of $1.8 million for stock-based compensation and the
amortization of intangible assets, compared to $1.5 million for the same
period in 2004. Net cash used in operating activities was $7.2 million for the
year ended December 31, 2005, compared to $22.2 million for the same period in
2004.
“Fiscal year 2005 was an exceptional year for DURECT as we executed on all
of the corporate objectives and key strategic initiatives that we previously
communicated. In 2006, we intend to make progress in our ongoing development
programs, move new programs into clinical development, build out our
commercial organization and continue to forge commercial alliances for our
products and technologies,” stated James E. Brown, DVM, President and CEO of
DURECT.
Highlights for DURECT in fiscal year 2005 include the following:
— We achieved positive preliminary data from an 81 patient Phase II study
of our SABER-Bupivacaine development product, which we believe has the
potential to be a significant advancement over the current commercially
available treatments for post-surgical pain.
— Positive results in a 200 patient Phase III study were announced for
Remoxy(TM) based on our ORADUR(TM) sustained release oral gel-cap
technology. Pain Therapeutics, Inc. sub-licensed to King
Pharmaceuticals the commercialization rights of Remoxy and the
remaining rights to ORADUR products licensed from DURECT incorporating
three other opioids.
— We achieved positive preliminary data from a Phase II study of our
transdermal sufentanil patch. In addition, we established a
commercialization partnership with Endo Pharmaceuticals on this
development product in March 2005 for the U.S. and Canadian markets. As
part of the agreement, Endo paid us an upfront fee of $10.0 million,
with the potential of additional milestone payments of approximately
$35.0 million. Endo will be solely responsible for funding the
remaining development expenses for this development product for the
U.S. and Canadian markets, in which we retain co-promotion rights for
this product. We retain all commercial rights in territories outside
the U.S. and Canada.
— In November 2005, we completed a secondary offering with net proceeds
of approximately $38.1 million after deducting underwriters’
commissions and other offering expenses.
— We continued to make significant progress on our other development
programs, including Memryte(TM) under development with Voyager
Pharmaceuticals for the treatment of Alzheimer’s disease, which has
moved into pivotal Phase III clinical studies.
Total revenues were $5.8 million and $28.6 million for the three months
and the year ended December 31, 2005, respectively, compared to $4.0 million
and $13.9 million for the same periods in 2004. The increase in total revenues
was primarily attributable to higher collaborative research and development
revenue recognized from our agreements with Pain Therapeutics, Voyager and
Endo Pharmaceuticals. Total revenues for the three months and the year ended
December 31, 2005 also included $547,000 and $1.8 million related to the
amortization of the $10.0 million upfront payment we received from Endo in
2005.
Research and development expenses were $7.7 million and $28.9 million for
the three months and the year ended December 31, 2005, respectively, compared
to $6.2 million and $24.2 million for the same periods in 2004. The increases
were primarily attributable to the higher development costs related to our
SABER-Bupivacaine, Memryte, Remoxy and transdermal patch development products
and other research and development programs, partially offset by lower
development expenses for CHRONOGESIC.
Selling, general and administrative expenses were $2.7 million and $10.7
million for the three months and the year ended December 31, 2005,
respectively, compared to $2.9 million and $9.7 million for the same periods
in 2004. The slight decrease in the three months ended December 31, 2005 was
primarily attributable to lower audit related expenses for the period compared
to the same period in 2004. The increase in selling, general and
administrative expenses in the year ended December 31, 2005 was primarily due
to higher patent, market research and employee related expenses.
Interest and other income was $911,000 and $2.3 million for the three
months and the year ended December 31, 2005, respectively, compared to
$317,000 and $1.2 million for the same periods in 2004. The increase in
interest and other income was primarily the result of higher balance and yield
in our cash and investments in the year ended December 31, 2005. We received
net proceeds of approximately $38.1 million from issuance of 8.2 million
shares of our common stock in the fourth quarter of 2005.
Interest expense was $1.0 million and $4.4 million for the three months
and the year ended December 31, 2005, respectively, compared with $1.2 million
and $4.5 million for the same periods in 2004. We incurred debt conversion
expense of $403,000 for the year ended December 31, 2005 in connection with
the early exchange and cancellation of approximately $2.7 million in principal
amount of our 6.25% Convertible Subordinated Notes through conversions into
our common stock in the third quarter of 2005. As of December 31, 2005, the
remaining principal balance of our 6.25% Convertible Subordinated Notes due
2008 was $57.3 million.
At December 31, 2005, we had cash and investments of $91.0 million,
including $2.0 million in restricted investments, compared with total cash and
investments of $61.8 million at December 31, 2004.
We expect total cash burn for the fiscal year 2006 to be in the range of
$31.0 million to $34.0 million, which includes interest payment of $3.6
million for the convertible notes.
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic debilitating diseases and
enable biotechnology products. Additional information about DURECT is
available at www.www.durect.com.
NOTE: CHRONOGESIC(R), SABER(TM), ORADUR(TM), DURIN(TM), TRANSDUR(TM) and
MICRODUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks
belong to their respective owners.
The statements in this press release regarding DURECT’s projected
financial results and development products, their designs and intended uses,
and DURECT’s and our collaborators’ product development and clinical trial
plans are forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such forward-
looking statements. Potential risks and uncertainties include, but are not
limited to, DURECT’s (and that of its third-party collaborators’, where
applicable) abilities to manage its growth and expenses, manage relationships
with third parties, finance its activities and operations, successfully enroll
and complete clinical trials, complete the design, development, and
manufacturing process development of the development product, obtain product
and manufacturing approvals from regulatory agencies and manufacture and
commercialize the development product, as well as marketplace acceptance of
the development product. Further information regarding these and other risks
is included in DURECT’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2005 filed with the SEC on October 13, 2005 under the heading
“Factors that may affect future results.”
DURECT CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three months ended Year ended
December 31, December 31,
2005 2004 2005 2004
(unaudited)(unaudited)(unaudited)(audited)
Product revenue, net $1,640 $1,515 $6,939 $6,416
Revenue from sale of intellectual
property rights -- -- 1,600 --
Collaborative research and
development and other revenue 4,136 2,508 20,032 7,437
Total revenues 5,776 4,023 28,571 13,853
Operating expenses:
Cost of revenues 882 612 2,815 2,729
Research and development 7,709 6,213 28,904 24,233
Selling, general and
administrative 2,665 2,922 10,680 9,747
Amortization of intangible
assets 300 303 1,209 1,249
Stock-based compensation(1) 138 26 591 204
Total operating expenses 11,694 10,076 44,199 38,162
Loss from operations (5,918) (6,053) (15,628) (24,309)
Other income (expense):
Interest income and other 911 317 2,270 1,236
Interest expense (1,034) (1,200) (4,363) (4,546)
Debt conversion expense -- -- (403) --
Net other expense (123) (883) (2,496) (3,310)
Loss before income taxes (6,041) (6,936) (18,124) (27,619)
Income tax provision -- 18 4 18
Net loss $(6,041) $(6,954) $(18,128) $(27,637)
Net loss per common share,
basic and diluted $(0.10) $(0.13) $(0.34) $(0.54)
Shares used in computing basic
and diluted net loss per share 58,201 51,839 53,719 51,507
(1) Stock-based compensation
related to the following:
Cost of revenues $-- $-- $-- $1
Research and development 131 1 237 157
Selling, general and administrative 7 25 354 46
$138 $26 $591 $204
DURECT CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
December 31, December 31,
2005 2004(1)
(unaudited)
Assets
Current assets:
Cash and cash equivalents, short term
investments and restricted investments $83,885 $41,797
Accounts receivable 4,488 2,481
Inventories 2,047 1,929
Prepaid expenses and other current assets 3,659 1,364
Total current assets 94,079 47,571
Property and equipment, net 7,304 7,112
Goodwill 6,399 6,399
Intangible assets, net 536 1,745
Long-term investments and restricted investments 7,112 20,016
Other non-current assets 1,984 2,625
Total assets $117,414 $85,468
Liabilities and stockholders' equity
Current liabilities:
Accounts payable, accrued liabilities and
deferred revenue $9,494 $5,006
Long-term obligations, current portion 383 483
Total current liabilities 9,877 5,489
Long-term obligations, noncurrent portion 64,185 61,589
Stockholders' equity 43,352 18,390
Total liabilities and stockholders' equity $117,414 $85,468
(1) Derived from audited financial statements.
SOURCE:
DURECT Corporation
02/08/2006
CONTACT:
Schond L. Greenway, Vice President, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417